<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991898</url>
  </required_header>
  <id_info>
    <org_study_id>2016LS107</org_study_id>
    <secondary_id>MT2016-17</secondary_id>
    <nct_id>NCT02991898</nct_id>
  </id_info>
  <brief_title>Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies</brief_title>
  <official_title>Adoptive Transfer of T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After an Umbilical Cord Blood Transplant for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center pilot study of a non-myeloablative umbilical cord blood transplant
      for the treatment of a hematological malignancy with a single infusion of T regulatory (Treg)
      given shortly after UCB transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Considering new technology for product.
  </why_stopped>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Actual">June 20, 2019</completion_date>
  <primary_completion_date type="Actual">June 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Survived</measure>
    <time_frame>2 years</time_frame>
    <description>Count of patients who survived 2 years post intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade II-IV aGVHD</measure>
    <time_frame>Assessed weekly until day 100, then day 180, 360</time_frame>
    <description>Probability of grade II-IV aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Treatment Related Mortality (TRM)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Bacterial, Viral and Fungal Infections</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Detectable Treg Cells at d14</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of patients with detectable Treg cells at day 14 post infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Immune Reconstitution</measure>
    <time_frame>Assessed at Day 4, weekly for 8 weeks</time_frame>
    <description>The proportion of patients with immune reconstitution. Continuous endpoints will be described by medians, ranges and interquartile ranges as well as means and standard deviations if normally distributed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Treg Cell Infusion Toxicity</measure>
    <time_frame>48 hours post infusion</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Treg Survival</measure>
    <time_frame>24 hours post infusion</time_frame>
    <description>Length of Treg survival after infusion of Treg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Donor Cell Chimerism</measure>
    <time_frame>Day +100</time_frame>
    <description>The incidence of chimerism in patients treated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Survived One Year Post-transplant</measure>
    <time_frame>1 year</time_frame>
    <description>The probability of survival, one year post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neutrophil Recovery</measure>
    <time_frame>Day 42</time_frame>
    <description>The incidence of neutrophil recovery, that is return of neutrophil counts to ≥ 5 X 10^8/L in treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Platelet Recovery</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of platelet recovery (return of platelet counts to &gt; 20,000/μL) in treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic GVHD</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of chronic GVHD in treated patients after one year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>Natural Killer Cell Malignancies</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Large-cell Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Marginal Zone B-Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Mantle-Cell Lymphoma</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Biphenotypic Leukemia</condition>
  <condition>Undifferentiated Leukemia</condition>
  <arm_group>
    <arm_group_label>Treg Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infusion of Treg</intervention_name>
    <description>Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose
Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.
Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.
DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion.</description>
    <arm_group_label>Treg Infusion</arm_group_label>
    <other_name>T regulatory cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be ≥18, but &lt; 70 years of age with no matched 7/8 or 8/8 sibling donor - patients
             ≥ 70 and ≤ 75 years of age may be eligible if they have a Co-Morbidity score ≤ 2
             (http://www.qxmd.com/calculate-online/hematology/hct-ci)

          -  UCB unit(s) composing the graft will be selected according to the current University
             of Minnesota umbilical cord blood graft selection algorithm and an additional cord
             blood unit to be used as the source to manufacture the Treg product. This UCB unit
             must be matched at 4-6/6 to the patient, considering HLA-A, B at the antigen level and
             DRB1 at the allele level

          -  Acute Leukemias: Must be in remission by morphology. Also a small percentage of blasts
             that is equivocal between marrow regeneration versus early relapse are acceptable
             provided there are no associated cytogenetic markers consistent with relapse. Refer to
             Section 5.2 for complete definitions.

          -  Burkitt's Lymphoma in CR2 or subsequent CR

          -  Natural Killer Cell Malignancies

          -  Chronic Myelogenous Leukemia: all types except refractory blast crisis. Chronic phase
             patients must have failed at least two different tyrosine-kinase inhibitors (TKIs), or
             been intolerant to all available TKIs or have T315I mutation.

          -  Myelodysplastic Syndrome: IPSS INT-2 or High Risk; R-IPSS High or Very High; WHO
             classification: RAEB-1, RAEB-2; Severe Cytopenias: ANC &lt; 0.8, Anemia or
             thrombocytopenia requiring transfusion; Poor or very poor risk cytogenetics based on
             IPSS or R-IPSS definitions; therapy-related MDS. Blasts must be be &lt; 5%, preferably &lt;
             20% blasts by morphology by bone marrow aspirate morphology.. If ≥ 5% blasts,
             chemotherapy for cytoreduction to &lt;5% blasts prior to transplantation may be
             considered.

          -  Chronic myeloid neoplasms, including but not limited to CMML with blasts must around
             5% blasts, preferably &lt; 20% blasts by morphology by bone marrow aspirate morphology.
             If ≥5% blasts, chemotherapy for cytoreduction to &lt;5% blasts prior to transplantation
             may be considered.

          -  Large-Cell Lymphoma, Hodgkin Lymphoma and Multiple Myeloma with chemotherapy sensitive
             disease that has failed or patients who are ineligible for an autologous transplant.

          -  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone
             B-Cell Lymphoma, Follicular Lymphoma, which have progressed within 12 months of
             achieving a partial or complete remission. Patients who had remissions lasting &gt; 12
             months are eligible after at least two prior therapies. Patients with bulky disease
             should be considered for debulking chemotherapy before transplant. Patients with
             refractory disease are eligible, unless has bulky disease and an estimated tumor
             doubling time of less than one month.

          -  Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible
             after initial therapy if chemotherapy sensitive.

          -  Patients must have undergone an autologous transplant ≤ 12 months prior to transplant
             on this study or have received multi-agent or immunosuppressive chemotherapy within 3
             months of the preparative regimen.

        Performance Status, Organ Function, Contraception Use

          -  Karnofsky score ≥ 70% (Appendix II)

          -  Adequate organ function within 14 days (30 days for cardiac and pulmonary) of
             registration on-study defined as:

               -  Renal: creatinine ≤ 2.0 mg/dL, for patient with a creatinine &gt; 1.2 mg/dL or a
                  history of renal dysfunction an estimated glomerular filtration rate ≥ 40
                  mL/min/1.73 m2 is required

               -  ALT, AST and alkaline phosphatase ≤ 5 x upper limit of normal and total bilirubin
                  ≤ 2.5 mg/dL except for patients with Gilbert's syndrome or hemolysis

               -  Pulmonary function: DLCO, FEV1, FVC ≥ 40% predicted, and absence of O2
                  requirements.

               -  Cardiac: Absence of decompensated congestive heart failure, or uncontrolled
                  arrhythmia and left ventricular ejection fraction ≥ 40%.

          -  Sexually active females of childbearing potential and males with partners of
             child-bearing potential must agree to use adequate birth control during study
             treatment.

          -  Voluntary written consent

        Exclusion Criteria:

          -  Untreated active infection

          -  History of HIV infection

          -  Pregnant or breast feeding. The agents used in this study may be teratogenic to a
             fetus and there is no information on the excretion of agents into breast milk. Females
             of childbearing potential must have a blood test or urine study within 14 days prior
             to registration to rule out pregnancy

          -  Prior allogeneic transplantation

          -  Less than 3 months from myeloablative conditioning for autologous transplantation (if
             applicable)

          -  Evidence of progressive disease by imaging modalities or biopsy - persistent PET
             activity, though possibly related to lymphoma, is not an exclusion criterion in the
             absence of CT changes indicating progression.

          -  CML in blast crisis

          -  Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on
             salvage therapy.

          -  Active central nervous system malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Brunstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <results_first_submitted>June 17, 2020</results_first_submitted>
  <results_first_submitted_qc>June 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2020</results_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>MDS</keyword>
  <keyword>CLL</keyword>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02991898/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treg Infusion</title>
          <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treg Infusion</title>
          <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Survived</title>
        <description>Count of patients who survived 2 years post intervention</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Survived</title>
          <description>Count of patients who survived 2 years post intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade II-IV aGVHD</title>
        <description>Probability of grade II-IV aGVHD</description>
        <time_frame>Assessed weekly until day 100, then day 180, 360</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade II-IV aGVHD</title>
          <description>Probability of grade II-IV aGVHD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Treatment Related Mortality (TRM)</title>
        <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Treatment Related Mortality (TRM)</title>
          <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Relapse</title>
        <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Relapse</title>
          <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incidence of Bacterial, Viral and Fungal Infections</title>
        <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Bacterial, Viral and Fungal Infections</title>
          <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Bacterial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Viral</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fungal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Detectable Treg Cells at d14</title>
        <description>The proportion of patients with detectable Treg cells at day 14 post infusion</description>
        <time_frame>14 days</time_frame>
        <population>Samples were not analyzed, and so data not available for reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Detectable Treg Cells at d14</title>
          <description>The proportion of patients with detectable Treg cells at day 14 post infusion</description>
          <population>Samples were not analyzed, and so data not available for reporting.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Immune Reconstitution</title>
        <description>The proportion of patients with immune reconstitution. Continuous endpoints will be described by medians, ranges and interquartile ranges as well as means and standard deviations if normally distributed.</description>
        <time_frame>Assessed at Day 4, weekly for 8 weeks</time_frame>
        <population>Samples were not analyzed, and so data not available for reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immune Reconstitution</title>
          <description>The proportion of patients with immune reconstitution. Continuous endpoints will be described by medians, ranges and interquartile ranges as well as means and standard deviations if normally distributed.</description>
          <population>Samples were not analyzed, and so data not available for reporting.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Treg Cell Infusion Toxicity</title>
        <description>Incidence of Adverse Events</description>
        <time_frame>48 hours post infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Treg Cell Infusion Toxicity</title>
          <description>Incidence of Adverse Events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Treg Survival</title>
        <description>Length of Treg survival after infusion of Treg.</description>
        <time_frame>24 hours post infusion</time_frame>
        <population>Samples were not analyzed, and so data not available for reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Treg Survival</title>
          <description>Length of Treg survival after infusion of Treg.</description>
          <population>Samples were not analyzed, and so data not available for reporting.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Donor Cell Chimerism</title>
        <description>The incidence of chimerism in patients treated</description>
        <time_frame>Day +100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Donor Cell Chimerism</title>
          <description>The incidence of chimerism in patients treated</description>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="50" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Survived One Year Post-transplant</title>
        <description>The probability of survival, one year post-treatment</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Survived One Year Post-transplant</title>
          <description>The probability of survival, one year post-treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neutrophil Recovery</title>
        <description>The incidence of neutrophil recovery, that is return of neutrophil counts to ≥ 5 X 10^8/L in treated patients</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutrophil Recovery</title>
          <description>The incidence of neutrophil recovery, that is return of neutrophil counts to ≥ 5 X 10^8/L in treated patients</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Platelet Recovery</title>
        <description>The incidence of platelet recovery (return of platelet counts to &gt; 20,000/μL) in treated patients</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Platelet Recovery</title>
          <description>The incidence of platelet recovery (return of platelet counts to &gt; 20,000/μL) in treated patients</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic GVHD</title>
        <description>The incidence of chronic GVHD in treated patients after one year</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treg Infusion</title>
            <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic GVHD</title>
          <description>The incidence of chronic GVHD in treated patients after one year</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treg Infusion</title>
          <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft Versus Host Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary leak syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Claudio Brustein</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-3918</phone>
      <email>bruns072@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

